NN 8555

Drug Profile

NN 8555

Alternative Names: Anti-NKG2D; IPH-2301; IPH-23XX; NN-8555; NNC-0142-0000-0002; NNC-0142-0002

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innate Pharma; Novo Nordisk
  • Developer Janssen Biotech; Novo Nordisk
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action NK cell lectin-like-receptor subfamily K antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Autoimmune disorders
  • Discontinued Crohn's disease; Inflammation

Most Recent Events

  • 02 Sep 2014 Discontinued - Phase-II for Crohn's disease in Europe (SC)
  • 02 Sep 2014 Discontinued - Phase-II for Inflammation in Europe (SC)
  • 30 Jan 2014 Phase-II clinical trials in Crohn's disease in Europe (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top